Further Introduction of DNA Methylation (DNAm) Arrays in Regular Diagnostics
- PMID: 35860466
- PMCID: PMC9289263
- DOI: 10.3389/fgene.2022.831452
Further Introduction of DNA Methylation (DNAm) Arrays in Regular Diagnostics
Abstract
Methylation tests have been used for decades in regular DNA diagnostics focusing primarily on Imprinting disorders or specific loci annotated to specific disease associated gene promotors. With the introduction of DNA methylation (DNAm) arrays such as the Illumina Infinium HumanMethylation450 Beadchip array or the Illumina Infinium Methylation EPIC Beadchip array (850 k), it has become feasible to study the epigenome in a timely and cost-effective way. This has led to new insights regarding the complexity of well-studied imprinting disorders such as the Beckwith Wiedemann syndrome, but it has also led to the introduction of tests such as EpiSign, implemented as a diagnostic test in which a single array experiment can be compared to databases with known episignatures of multiple genetic disorders, especially neurodevelopmental disorders. The successful use of such DNAm tests is rapidly expanding. More and more disorders are found to be associated with discrete episignatures which enables fast and definite diagnoses, as we have shown. The first examples of environmentally induced clinical disorders characterized by discrete aberrant DNAm are discussed underlining the broad application of DNAm testing in regular diagnostics. Here we discuss exemplary findings in our laboratory covering this broad range of applications and we discuss further use of DNAm tests in the near future.
Keywords: DNAm arrays; epigenome; episign; genome diagnostics; genomic imprinting.
Copyright © 2022 Mannens, Lombardi, Alders, Henneman and Bliek.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
DNA methylation episignature and comparative epigenomic profiling of HNRNPU-related neurodevelopmental disorder.Genet Med. 2023 Aug;25(8):100871. doi: 10.1016/j.gim.2023.100871. Epub 2023 Apr 28. Genet Med. 2023. PMID: 37120726
-
Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array.Epigenetics Chromatin. 2013 Mar 3;6(1):4. doi: 10.1186/1756-8935-6-4. Epigenetics Chromatin. 2013. PMID: 23452981 Free PMC article.
-
Critical evaluation of the reliability of DNA methylation probes on the Illumina MethylationEPIC BeadChip microarrays.Res Sq [Preprint]. 2023 Oct 17:rs.3.rs-3068938. doi: 10.21203/rs.3.rs-3068938/v2. Res Sq. 2023. Update in: Epigenetics. 2024 Dec;19(1):2333660. doi: 10.1080/15592294.2024.2333660. PMID: 37461726 Free PMC article. Updated. Preprint.
-
DNA Methylation Episignatures in Neurodevelopmental Disorders Associated with Large Structural Copy Number Variants: Clinical Implications.Int J Mol Sci. 2022 Jul 16;23(14):7862. doi: 10.3390/ijms23147862. Int J Mol Sci. 2022. PMID: 35887210 Free PMC article. Review.
-
Anatomy of DNA methylation signatures: Emerging insights and applications.Am J Hum Genet. 2021 Aug 5;108(8):1359-1366. doi: 10.1016/j.ajhg.2021.06.015. Epub 2021 Jul 22. Am J Hum Genet. 2021. PMID: 34297908 Free PMC article. Review.
Cited by
-
DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis.Biomedicines. 2023 Jul 13;11(7):1987. doi: 10.3390/biomedicines11071987. Biomedicines. 2023. PMID: 37509625 Free PMC article. Review.
-
Overgrowth syndromes, diagnosis and management.Curr Opin Pediatr. 2023 Dec 1;35(6):620-630. doi: 10.1097/MOP.0000000000001298. Epub 2023 Oct 4. Curr Opin Pediatr. 2023. PMID: 37791807 Free PMC article. Review.
-
Imprinting disorders.Nat Rev Dis Primers. 2023 Jun 29;9(1):33. doi: 10.1038/s41572-023-00443-4. Nat Rev Dis Primers. 2023. PMID: 37386011 Review.
-
mLiftOver: harmonizing data across Infinium DNA methylation platforms.Bioinformatics. 2024 Jul 1;40(7):btae423. doi: 10.1093/bioinformatics/btae423. Bioinformatics. 2024. PMID: 38963309 Free PMC article.
-
Molecular mechanisms of human overgrowth and use of omics in its diagnostics: chances and challenges.Front Genet. 2024 Jun 4;15:1382371. doi: 10.3389/fgene.2024.1382371. eCollection 2024. Front Genet. 2024. PMID: 38894719 Free PMC article. Review.
References
-
- Agha G., Mendelson M. M., Ward-Caviness C. K., Joehanes R., Huan T., Gondalia R., et al. (2019). Blood Leukocyte DNA Methylation Predicts Risk of Future Myocardial Infarction and Coronary Heart Disease. Circulation 140 (8), 645–657. Epub 2019 Aug 19. PMID: 31424985; PMCID: PMC6812683. 10.1161/Circulation.AHA.118.039357 - DOI - PMC - PubMed
-
- Al-Jawahiri R., Foroutan A., Kerkhof J., McConkey H., Levy M., Haghshenas S., et al. (2022). SOX11 Variants Cause a Neurodevelopmental Disorder with Infrequent Ocular Malformations and Hypogonadotropic Hypogonadism and with Distinct DNA Methylation Profile. Genet. Med. 24 (6), 1261–1273. Epub 2022 Mar 24. PMID: 35341651. 10.1016/j.gim.2022.02.013 - DOI - PMC - PubMed
-
- Aref-Eshghi E., Kerkhof J., Pedro V. P., Barat-Houari M., Ruiz-Pallares N., Andrau J.-C., et al. (2020). Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders. Am. J. Hum. Genet. 106 (3), 356–370. 10.1016/j.ajhg.2020.01.019 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources